UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Epilepsia (Copenhagen), 2023-10, Vol.64 (10), p.2653-2666

2023

Volltextzugriff (PDF)

Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting

The journal of clinical psychiatry, 2007-05, Vol.68 (5), p.711

2007

Volltextzugriff (PDF)

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study

Epilepsia (Copenhagen), 2023-01, Vol.64 (1), p.139-151

2023

Volltextzugriff (PDF)

Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments

European journal of paediatric neurology, 2022-07, Vol.39, p.35-39

2022

Volltextzugriff (PDF)

A randomized controlled trial of ganaxolone in posttraumatic stress disorder

Psychopharmacology, 2017-08, Vol.234 (15), p.2245-2257

2017

Volltextzugriff (PDF)

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2000-04, Vol.283 (14), p.1837

2000

Volltextzugriff (PDF)

Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study

The American journal of psychiatry, 2001-12, Vol.158 (12), p.1974-1981

2001

Volltextzugriff (PDF)

Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies

The journal of clinical psychiatry, 2006-10, Vol.67 (10), p.1624

2006

Volltextzugriff (PDF)

Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment

The journal of clinical psychiatry, 2001-05, Vol.62 (5), p.325

2001

Volltextzugriff (PDF)

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial

JAMA neurology, 2020-03, Vol.77 (3), p.300

2020

Volltextzugriff (PDF)

Fenfluramine acts as a positive modulator of sigma-1 receptors

Epilepsy & behavior, 2020-04, Vol.105, p.106989-106989, Article 106989

2020

Volltextzugriff (PDF)

Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo

Epilepsy & behavior, 2022-02, Vol.127, p.108526, Article 108526

2022

Volltextzugriff (PDF)

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2019-12, Vol.394 (10216), p.2243-2254

2019

Volltextzugriff (PDF)

Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

Epilepsia (Copenhagen), 2020-11, Vol.61 (11), p.2396-2404

2020

Volltextzugriff (PDF)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

Epilepsia (Copenhagen), 2020-11, Vol.61 (11), p.2386-2395

2020

Volltextzugriff (PDF)

663. An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look beyond Serotonin

Biological psychiatry (1969), 2017-05, Vol.81 (10), p.S268-S269

2017

Volltextzugriff (PDF)

An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look beyond Serotonin

Biological psychiatry (1969), 2017, Vol.81 (10), p.S268-S269

2017

Volltextzugriff (PDF)

Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome

Epilepsy & behavior, 2021-08, Vol.121 (Pt A), p.108024, Article 108024

2021

Volltextzugriff (PDF)

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2years

Epilepsia (Copenhagen), 2022-10, Vol.63 (10), p.2664-2670

2022

Volltextzugriff (PDF)

Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment

Epilepsy & behavior, 2023-01, Vol.138, p.108994, Article 108994

2023

Volltextzugriff (PDF)

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years

Epilepsia (Copenhagen), 2022-10, Vol.63 (10), p.2664-2670

2022

Volltextzugriff (PDF)

Fenfluramine HCl Provides Long-Term Clinically Meaningful Reduction in Seizure Frequency: Results of an Open-Label Extension Study

Epilepsy & behavior, 2019-12, Vol.101, p.106790, Article 106790

2019

Volltextzugriff (PDF)

Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth

Epilepsy & behavior, 2021-09, Vol.122, p.108212-108212, Article 108212

2021

Volltextzugriff (PDF)

Effect of ZX008 (Fenfluramine HCl Oral Solution) on Total Seizures in Dravet Syndrome

Epilepsy & behavior, 2019-12, Vol.101, p.106789, Article 106789

2019

Volltextzugriff (PDF)

Long-Term Cardiovascular Safety of Fenfluramine HCl in the Treatment of Dravet Syndrome: Interim Analysis of an Open-Label Safety Extension Study

Epilepsy & behavior, 2019-12, Vol.101, p.106791, Article 106791

2019

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)
Dissertationen
(1)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study

Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments

A randomized controlled trial of ganaxolone in posttraumatic stress disorder

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study

Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies

Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial

Fenfluramine acts as a positive modulator of sigma-1 receptors

Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

663. An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look beyond Serotonin

An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look beyond Serotonin

Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2years

Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment

Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years

Fenfluramine HCl Provides Long-Term Clinically Meaningful Reduction in Seizure Frequency: Results of an Open-Label Extension Study

Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth

Effect of ZX008 (Fenfluramine HCl Oral Solution) on Total Seizures in Dravet Syndrome

Long-Term Cardiovascular Safety of Fenfluramine HCl in the Treatment of Dravet Syndrome: Interim Analysis of an Open-Label Safety Extension Study

Suchergebnisse filtern